RESUMEN
Most vaccines for diseases in low- and middle-income countries fail to be developed because of weak or absent market incentives. Conquering diseases such as tuberculosis, HIV, malaria, and Ebola, as well as illnesses caused by multidrug-resistant pathogens, requires considerable investment and a new sustainable model of vaccine development involving close collaborations between public and private sectors.
Asunto(s)
Salud Global , Vacunas/uso terapéutico , Vacunas contra el Virus del Ébola/administración & dosificación , Vacunas contra el Virus del Ébola/uso terapéutico , Humanos , Esquemas de Inmunización , Neisseria meningitidis Serogrupo A/inmunología , Neisseria meningitidis Serogrupo A/patogenicidad , Neisseria meningitidis Serogrupo B/inmunología , Neisseria meningitidis Serogrupo B/patogenicidad , Vacunas/administración & dosificación , Organización Mundial de la SaludRESUMEN
Whole genome sequencing analysis of 100 Neisseria meningitidis serogroup A isolates has revealed that the csaABCD-ctrABCD-ctrEF capsule polysaccharide synthesis locus represents a spontaneous point mutation hotspot. Structural and functional properties of the capsule of 11 carriage and two disease isolates with non-synonymous point mutations or stop codons in capsule synthesis genes were analyzed for their capsular polysaccharide expression, recognition by antibodies and sensitivity to bactericidal killing. Eight of eleven carriage isolates presenting capsule locus mutations expressed no or reduced amounts of capsule. One isolate with a stop codon in the O-acetyltransferase gene expressed non-O-acetylated polysaccharide, and was not recognized by anti-capsule antibodies. Capsule and O-acetylation deficient mutants were resistant to complement deposition and killing mediated by anti-capsular antibodies, but not by anti-lipopolysaccharide antibodies. Two capsule polymerase mutants, one carriage and one case isolate, showed capsule over-expression and increased resistance against bactericidal activity of both capsule- and lipopolysaccharide-specific antibodies. Meningococci have developed multiple strategies for changing capsule expression and structure, which is relevant both for colonization and virulence. Here we show that point mutations in the capsule synthesis genes substantially contribute to the repertoire of genetic mechanisms in natural populations leading to variability in capsule expression.
Asunto(s)
Cápsulas Bacterianas/genética , Cápsulas Bacterianas/metabolismo , Neisseria meningitidis Serogrupo A/genética , Neisseria meningitidis Serogrupo A/patogenicidad , Mutación Puntual , Animales , Anticuerpos Antibacterianos/farmacología , Cápsulas Bacterianas/química , Cápsulas Bacterianas/efectos de los fármacos , Burkina Faso , Portador Sano/microbiología , Variación Genética , Genoma Bacteriano , Ghana , Humanos , Inmunidad Colectiva , Meningitis Meningocócica/microbiología , Ratones , Neisseria meningitidis Serogrupo A/química , Neisseria meningitidis Serogrupo A/inmunología , Polisacáridos Bacterianos/genética , Virulencia/genéticaAsunto(s)
Infección de Laboratorio/microbiología , Meningitis Meningocócica/transmisión , Neisseria meningitidis Serogrupo A/aislamiento & purificación , Enfermedades Profesionales/microbiología , Adulto , Humanos , Capacitación en Servicio , Infección de Laboratorio/prevención & control , Infección de Laboratorio/transmisión , Masculino , Programas Obligatorios , Personal de Laboratorio Clínico/educación , Meningitis Meningocócica/diagnóstico , Meningitis Meningocócica/prevención & control , Meningitis Meningocócica/terapia , Vacunas Meningococicas , Neisseria meningitidis Serogrupo A/patogenicidad , Enfermedades Profesionales/prevención & control , RiesgoRESUMEN
INTRODUCTION: MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A, the major cause of meningitis outbreaks in sub-Saharan Africa. In Niger, the MenAfriVac introduction campaign was conducted in the District of Filingue, during September 2010, targeting 392,211 individuals aged 1-29 years. We set up an enhanced spontaneous surveillance system to monitor adverse events following immunization (AEFI) during the campaign period and 42 days thereafter. METHODS: All the 33 health centres of the district have been designated as surveillance units, which reported AEFIs on a daily basis to the health district headquarters. Health care workers were instructed to screen patients presenting with predefined conditions of interest and patients spontaneously presenting at units or at vaccination posts with complaints after vaccination. Cases were classified as serious (resulting in death, hospitalization or long-term disability) or minor. A National Expert Committee was established to determine if serious cases were causally associated with the vaccine. RESULTS: In total, 356,532 vaccine doses were administered. During 61 days of monitoring, 82 suspected AEFIs were reported: 16 severe and 66 minor. The cumulative incidence was of 23.0 per 100,000 doses. Among severe cases, 14 were classified as coincidences, one urticaria complicated by respiratory distress was classified as a probable vaccine reaction, and one death was unclassifiable because post-mortem information was unavailable. The number of units that reported at least one case was 19/33 (57.6%). CONCLUSIONS: Although these results are limited by underreporting of cases, we did not identify safety concerns with MenAfriVac. The lessons learned from this experience should be used to reinforce the national pharmacovigilance system in Niger to make it complaint with international standards. In order to do so, we recommend using a lighter system for routine; and conducting regular training and supervisory activities to increase its acceptance among local health workers.
Asunto(s)
Vacunas Meningococicas/efectos adversos , Vigilancia de la Población , Vacunación/efectos adversos , Adolescente , Sistemas de Registro de Reacción Adversa a Medicamentos , África del Sur del Sahara , Niño , Preescolar , Estudios de Factibilidad , Femenino , Humanos , Masculino , Meningitis Meningocócica/prevención & control , Neisseria meningitidis Serogrupo A/patogenicidad , Niger/epidemiología , Vacunas Conjugadas/efectos adversosRESUMEN
BACKGROUND: Meningococcal epidemics in Africa are generally caused by capsular group A strains, but W-135 or X strains also cause epidemics in this region. Factor H-binding protein (fHbp) is a novel antigen being investigated for use in group B vaccines. Little is known about fHbp in strains from other capsular groups. METHODS: We investigated fHbp in 35 group A, W-135, and X strains from Africa. RESULTS: The 22 group A isolates, which included each of the sequence types (STs) responsible for epidemics since 1963, and 4 group X and 3 group W-135 isolates from recent epidemics had genes encoding fHbp in antigenic variant group 1. The remaining 6 W-135 isolates had fHbp variant 2. Within each fHbp variant group, there was 92%-100% amino acid identity, and the proteins expressed conserved epitopes recognized by bactericidal monoclonal antibodies. Serum samples obtained from mice vaccinated with native outer membrane vesicle vaccines from mutants engineered to express fHbp variants had broad bactericidal activity against group A, W-135, or X strains. CONCLUSIONS: Despite extensive natural exposure of the African population, fHbp is conserved among African strains. A native outer membrane vesicle vaccine that expresses fHbp variants can potentially elicit protective antibodies against strains from all capsular groups that cause epidemics in the region.
Asunto(s)
Proteínas del Sistema Complemento/inmunología , Meningitis Meningocócica/genética , Neisseria meningitidis Serogrupo A/patogenicidad , Neisseria meningitidis Serogrupo W-135/patogenicidad , África/epidemiología , Anticuerpos Antibacterianos/inmunología , Antígenos Bacterianos/metabolismo , Proteínas Bacterianas/metabolismo , Factor H de Complemento/inmunología , Factor H de Complemento/metabolismo , Epítopos/química , Epítopos/inmunología , Humanos , Meningitis Meningocócica/epidemiología , Meningitis Meningocócica/inmunología , Meningitis Meningocócica/prevención & control , Neisseria meningitidis/genética , Neisseria meningitidis/aislamiento & purificación , Neisseria meningitidis/patogenicidad , Neisseria meningitidis Serogrupo A/genética , Neisseria meningitidis Serogrupo A/aislamiento & purificación , Neisseria meningitidis Serogrupo W-135/genética , Neisseria meningitidis Serogrupo W-135/aislamiento & purificación , Reacción en Cadena de la PolimerasaRESUMEN
Neisseria meningitidis type A (MenA) is a Gram-negative encapsulated bacterium that may cause explosive epidemics of meningitis, especially in the sub-Saharan region of Africa. The development and manufacture of an efficient glycoconjugate vaccine against Neisseria meningitidis A is greatly hampered by the poor hydrolytic stability of its capsular polysaccharide, which is made up of (1-->6)-linked 2-acetamido-2-deoxy-alpha-D-mannopyranosyl phosphate repeating units. Since this chemical lability is a product of the inherent instability of the phosphodiester bridges, here we report the synthesis of phosphonoester-linked oligomers of N-acetyl mannosamine as candidates for stabilised analogues of the corresponding phosphate-bridged saccharides. The installation of each interglycosidic phosphonoester linkage was achieved by Mitsunobu coupling of a glycosyl C-phosphonate building block with the 6-OH moiety of a mannosaminyl residue. Each of the synthesised compounds contains an O-linked aminopropyl spacer at its reducing end (alpha- or beta-oriented) to allow for protein conjugation. The relative affinities of the synthetic molecules were investigated by a competitive ELISA assay and showed that a human polyclonal anti-MenA serum can recognise both the phosphonoester-bridged fragments 1-3 and their monomeric subunits, glycosides 20 and 21. Moreover, the biological results suggest that the abilities of these compounds to inhibit the binding of a specific antibody to MenA polysaccharide are dependent on the chain lengths of the molecules, but independent on the orientations of the anomeric linkers.
Asunto(s)
Cápsulas Bacterianas/química , Neisseria meningitidis Serogrupo A/química , Organofosfonatos/síntesis química , Polisacáridos Bacterianos/química , Cápsulas Bacterianas/inmunología , Ensayo de Inmunoadsorción Enzimática , Neisseria meningitidis Serogrupo A/inmunología , Neisseria meningitidis Serogrupo A/patogenicidad , Polisacáridos Bacterianos/inmunologíaRESUMEN
Although Neisseria meningitidis is a highly variable organism, most invasive disease is caused by a minority of genotypes. Hypervirulent lineages have been identified and their pandemic spread has been traced. During a longitudinal meningococcal colonization study in a district of northern Ghana clonal waves of carriage and disease were observed. Genetic diversification of genoclouds was analysed by pulsed field gel electrophoretic (PFGE) analysis of isolates from healthy carriers and from meningitis patients. Even during the limited time of persistence in the district, microevolution of the dominating genoclouds took place. Population genomic analyses are required to understand the genetic basis for the emergence of new lineages with epidemic potential, which is of crucial importance for the development of long-term global vaccination strategies against meningococcal disease.
Asunto(s)
Variación Genética , Meningitis Meningocócica/epidemiología , Neisseria meningitidis/genética , ADN Bacteriano/análisis , ADN Bacteriano/genética , Electroforesis en Gel de Campo Pulsado , Geografía , Ghana/epidemiología , Humanos , Meningitis Meningocócica/inmunología , Neisseria meningitidis/clasificación , Neisseria meningitidis/patogenicidad , Neisseria meningitidis Serogrupo A/clasificación , Neisseria meningitidis Serogrupo A/genética , Neisseria meningitidis Serogrupo A/patogenicidad , Neisseria meningitidis Serogrupo W-135/clasificación , Neisseria meningitidis Serogrupo W-135/genética , Neisseria meningitidis Serogrupo W-135/patogenicidad , Serotipificación , Factores de Tiempo , VirulenciaRESUMEN
We developed two Neisseria meningitidis multiplex PCR assays to be used consecutively that allow determination of the serogroup and capsular status of serogroup A, B, C, 29E, W135, X, and Y cnl-3/cnl-1-like-containing N. meningitidis isolates by direct analysis of the amplicon size. These assays offer a rapid and simple method of serogrouping N. meningitidis.
Asunto(s)
Neisseria meningitidis/clasificación , Neisseria meningitidis/genética , Reacción en Cadena de la Polimerasa/métodos , Serotipificación/métodos , Secuencia de Bases , Portador Sano/microbiología , Cartilla de ADN/genética , ADN Bacteriano/genética , Humanos , Infecciones Meningocócicas/microbiología , Neisseria meningitidis/patogenicidad , Neisseria meningitidis Serogrupo A/clasificación , Neisseria meningitidis Serogrupo A/genética , Neisseria meningitidis Serogrupo A/patogenicidad , Neisseria meningitidis Serogrupo B/clasificación , Neisseria meningitidis Serogrupo B/genética , Neisseria meningitidis Serogrupo B/patogenicidad , Neisseria meningitidis Serogrupo C/clasificación , Neisseria meningitidis Serogrupo C/genética , Neisseria meningitidis Serogrupo C/patogenicidad , Neisseria meningitidis Serogrupo W-135/clasificación , Neisseria meningitidis Serogrupo W-135/genética , Neisseria meningitidis Serogrupo W-135/patogenicidad , Neisseria meningitidis Serogrupo Y/clasificación , Neisseria meningitidis Serogrupo Y/genética , Neisseria meningitidis Serogrupo Y/patogenicidad , Reacción en Cadena de la Polimerasa/estadística & datos numéricos , Sensibilidad y Especificidad , Serotipificación/estadística & datos numéricos , Virulencia/genéticaRESUMEN
Serogroup A Neisseria meningitidis organisms of the subgroup III have caused epidemics of meningitis in sub-Saharan Africa since their introduction into the continent in 1987. The population structure of these bacteria is basically clonal, and these meningococci are strikingly similar in their major outer membrane antigens PorA and PorB. Protein-based vaccines might be an alternative to prevent epidemics caused by these meningococci; thus, we developed an outer membrane vesicle (OMV) vaccine from a serogroup A meningococcal strain of subgroup III. The serogroup A OMV vaccine was highly immunogenic in mice and elicited significant bactericidal activity towards several other serogroup A meningococci of subgroup III. The IgG antibodies generated were in immunoblot shown to be mainly directed towards the PorA outer membrane protein. The results presented demonstrate the potential of an OMV vaccine as an optional strategy to protect against meningococcal disease caused by serogroup A in Africa.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Proteínas de la Membrana Bacteriana Externa/inmunología , Meningitis Meningocócica/prevención & control , Vacunas Meningococicas/inmunología , Neisseria meningitidis Serogrupo A/inmunología , Porinas/inmunología , Animales , Antígenos Bacterianos/administración & dosificación , Antígenos Bacterianos/inmunología , Antígenos Bacterianos/aislamiento & purificación , Immunoblotting , Inmunoglobulina G/sangre , Vacunas Meningococicas/química , Ratones , Neisseria meningitidis Serogrupo A/patogenicidad , Vacunación , Vacunas de Subunidad/inmunologíaRESUMEN
OBJECTIVE: To discuss the role of meningococcal vaccine in prevention of meningococcal disease. DATA SOURCES: A MEDLINE search (1966-June 2001) was performed to identify key literature. Search terms included, but were not limited to, meningococcal vaccines, meningococcal meningitis, meningococcal infection, and meningococcus. The search was limited to English-language literature and references dealing with humans. The MEDLINE search was supplemented by a hand search of various bibliographies. DATA SYNTHESIS: The impact of meningococcal disease has caused national and regional organizations to develop recommendations for use of meningococcal vaccine. Even though the meningococcal vaccine can provide benefit, limitations exist. The available vaccine does not cover all meningococcal strains and is not useful in all age groups. The appropriate target groups for prevention of disease through vaccination have been difficult to determine; vaccine use in college students is especially controversial. CONCLUSIONS: Although a meningococcal vaccine is available, meningococcus causes significant morbidity and mortality. Controversy exists over the meningococcal vaccine and its use. Students entering college who will be living in dormitories should be informed of the increased risk of meningococcal disease and be offered vaccination.